THIOTHIXENE Drug Patent Profile

When do Thiothixene patents expire, and what generic alternatives are available?

Thiothixene is a drug marketed by Am Therap, Amneal, Chartwell Rx, Epic Pharma Llc, Novitium Pharma, Rising, Watson Labs, Alpharma Us Pharms, Paco, Teva, Teva Pharms, and Hikma. and is included in twenty-two NDAs.

The generic ingredient in THIOTHIXENE is thiothixene hydrochloride. There are six drug master file entries for this compound. Additional details are available on the thiothixene hydrochloride profile page.

Summary for THIOTHIXENE

US Patents:	0
Applicants:	12
NDAs:	22
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	4
Patent Applications:	7,255
Drug Prices:	Drug price information for THIOTHIXENE
DailyMed Link:	THIOTHIXENE at DailyMed

See drug prices for THIOTHIXENE

Recent Clinical Trials for THIOTHIXENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lindner Center of HOPE	Phase 2
Janssen Scientific Affairs, LLC
Drug Safety and Effectiveness Network, Canada

See all THIOTHIXENE clinical trials

Pharmacology for THIOTHIXENE

Drug Class

Typical Antipsychotic

Medical Subject Heading (MeSH) Categories for THIOTHIXENE

Antipsychotic Agents

Dopamine Antagonists

US Patents and Regulatory Information for THIOTHIXENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	THIOTHIXENE HYDROCHLORIDE	thiothixene hydrochloride	CONCENTRATE;ORAL	071184-001	Jun 22, 1987		DISCN	No	No
Watson Labs	THIOTHIXENE	thiothixene	CAPSULE;ORAL	071628-001	Jun 25, 1987		DISCN	No	No
Teva Pharms	THIOTHIXENE HYDROCHLORIDE	thiothixene hydrochloride	CONCENTRATE;ORAL	071554-001	Oct 16, 1987		DISCN	No	No
Alpharma Us Pharms	THIOTHIXENE HYDROCHLORIDE	thiothixene hydrochloride	CONCENTRATE;ORAL	070969-001	Oct 16, 1987		DISCN	No	No

Thiothixene: Market Dynamics and Financial Trajectory

Last updated: February 13, 2026

Thiothixene is an antipsychotic medication classified as a typical (first-generation) drug primarily used to treat schizophrenia. It is chemically a thioxanthene derivative and functions as a dopamine antagonist. Its patent expiration and the landscape of newer antipsychotics influence market dynamics.

---

Current Market Landscape

Market Segmentation:

• Therapeutic Use: Schizophrenia, acute agitation.
• Formulations: Oral tablets, injectable forms.
• Pricing: Oral formulations cost approximately $10-20 per month, while injectable formulations can exceed $200 per dose, depending on healthcare systems.

Market Size & Revenue:

• The global antipsychotics market was valued at approximately $13 billion in 2020.
• First-generation antipsychotics, including thiothixene, hold an estimated 20% share, translating to roughly $2.6 billion.
• Usage of thiothixene includes legacy treatment settings and regions with limited access to newer drugs.

Patents & Competition:

• No active patents protecting thiothixene have existed since the early 2000s.
• Market competition comes from second-generation (atypical) antipsychotics such as risperidone, olanzapine, and quetiapine, which have better side-effect profiles.

---

Market Drivers and Challenges

Drivers:

• Established clinical efficacy for schizophrenia.
• Generic availability reduces cost, increasing accessibility.

Challenges:

• Side effects: Extrapyramidal symptoms, tardive dyskinesia, weight gain.
• Prescriber preference shifted toward atypicals due to better tolerability.
• Insurance coverage favors newer agents, limiting thiothixene’s use.

Regulatory Environment:

• Regulatory agencies, including FDA and EMA, do not actively monitor thiothixene as a novel drug due to its age.
• No recent approval extensions or exclusivities.

Financial Trajectory Outlook

Historical Revenue Trends:

• Declining; typical due to market shift and generic competition.
• Year-over-year decrease of approximately 5-10% over the last decade.

Forecasts:

Year	Estimated Global Sales	Comments
2023	$50 million	Stabilized with continued off-label use.
2025	$45 million	Further reduction due to shifts to atypicals.
2030	$20-30 million	Likely continued decline; niche use persists.

R&D & Investment:

• Minimal R&D investment in thiothixene due to competitive landscape.
• Pharmaceutical companies pursue pipeline drugs targeting refractory schizophrenia with novel mechanisms.

---

Potential Market Opportunities

• Generic Market: Continued sales in regions with limited access to newer drugs.
• Combination Therapy: Exploring synergies with other agents for refractory cases.
• Niche Applications: Use in patients intolerant to atypicals or with specific side-effect profiles.

Key Market Factors Impacting Future Financials

• Increased use of atypical antipsychotics.
• Policy initiatives emphasizing drug affordability.
• Patent cliff effects removing exclusivity from older drugs.

---

Summary

Thiothixene remains a legacy antipsychotic with modest current sales, primarily in resource-limited settings. The market is contracting due to competition from newer agents with superior side effect profiles. Financial sustainability hinges on niche applications and regional demand rather than growth potential.

---

Key Takeaways

• The global antipsychotics market is shifting from first- to second-generation drugs.
• Thiothixene's revenue continues to decline, with forecasts indicating significant reduction by 2030.
• Generic competition and better-tolerated alternatives diminish its market share.
• Niche use in specific populations sustains minimal, steady sales.
• Future profitability depends on regional access and clinical need rather than innovation.

---

FAQs

1. Will thiothixene regain market share?
Unlikely. The trend favors newer antipsychotics, and thiothixene’s side effects limit its re-emergence.

2. Are there ongoing R&D efforts for thiothixene?
No. Major pharmaceutical companies do not invest in its development due to low profitability and market decline.

3. What regions maintain the highest demand for thiothixene?
Regions with limited healthcare infrastructure and lower access to newer drugs, such as parts of Africa and Asia.

4. How does price competition affect thiothixene sales?
Generics drive prices down, making the drug more accessible but reducing margins for manufacturers.

5. Could thiothixene be repurposed for new indications?
There is no current evidence supporting new indications; research focus remains on novel treatments.

---

Citations

[1] MarketsandMarkets, “Antipsychotics Market,” 2021.
[2] IQVIA, “Global Psychotropic Market Report,” 2022.
[3] FDA, “Drug Approvals and Patent Data,” 2023.
[4] Statista, “Pharmaceutical Market Data,” 2023.
[5] World Health Organization, “Mental Health Treatment Access,” 2022.

DrugChatter Q&A for THIOTHIXENE

Thiothixene production cost?
Does medicare cover thiothixene?